Young-Jin Kim
Directeur Général chez HANDOK INC.
Fortune : 20 M $ au 30/06/2024
Profil
Young-Jin Kim is currently the Chairman & Co-Chief Executive Officer at Handok, Inc. since 1996.
He is also the Chairman at Genexine, Inc. since 2015, the Director at Rezolute, Inc. since 2022, and the Director at TRIGR Therapeutics, Inc. He previously served as the Vice President at The Korea Chamber of Commerce & Industry starting from 2009.
In addition, he was the President of Handok Jeseok Foundation since 2014 and the President of Korean German Society since 2010.
Prior to his current positions, he held the role of Chief Executive Officer at Hoechst Marion Roussel, Inc. He also served as the Chief Executive Officer & Country Manager at Sanofi-Aventis Korea Co., Ltd.
from 1991 to 2005.
Furthermore, he was the Chief Executive Officer at Korea Hoechst Marion Roussel during the same period.
He held the position of Vice Chairman at Korea Pharmaceutical Manufacturers Association from 1999 to 2007.
He was also a Director at pH Pharma Co., Ltd.
Moreover, he served as a Director at Korean German Chamber of Commerce & Industry from 2010 to 2016.
He started his career as the Country Manager at Hoechst AG from 1991 to 2005.
Mr. Kim obtained an MBA from Kelley School of Business in 1984.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HANDOK, INC.
13,65% | 01/07/2024 | 1 878 397 ( 13,65% ) | 19 M $ | 30/06/2024 |
REZOLUTE, INC.
0,22% | 18/03/2024 | 115 450 ( 0,22% ) | 496 435 $ | 30/06/2024 |
Postes actifs de Young-Jin Kim
| Sociétés | Poste | Début |
|---|---|---|
| HANDOK INC. | Directeur Général | 01/01/1996 |
| GENEXINE, INC. | Président | - |
| REZOLUTE, INC. | Directeur/Membre du Conseil | 04/05/2022 |
The Korea Chamber of Commerce & Industry
 The Korea Chamber of Commerce & Industry Miscellaneous Commercial ServicesCommercial Services The Korea Chamber of Commerce & Industry (KCCI) is a business organization that provides resources, publications, events, and networks for its members. The organization is based in Seoul, North Korea and has overseas offices. The KCCI advocates for its members and partners with other organizations to promote bilateral economic cooperation. The KCCI also provides economic data and policy issues publications and hosts business forums and roundtables. Recently, the KCCI hosted a successful business forum with over 600 attendees, including political and business leaders from both countries. The Financial Services Commission identified five bank holding companies and five banks as domestic systemically important banks for 2024, and those identified as D-SIBs are required to set aside an additional common equity capital of 1.0, and the higher loss absorbency requirement will take effect on January 1, 2024. | Corporate Officer/Principal | 01/01/2009 |
| Handok Jeseok Foundation | President | 01/01/2014 |
TRIGR Therapeutics, Inc.
 TRIGR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trigr Therapeutics, Inc. engages in pharmaceuticals industry group. The company is headquartered in Irvine, CA. | Directeur/Membre du Conseil | - |
| Korean German Society | President | 01/01/2010 |
Anciens postes connus de Young-Jin Kim
| Sociétés | Poste | Fin |
|---|---|---|
| Korean German Chamber of Commerce & Industry | Directeur/Membre du Conseil | 01/01/2016 |
| Korea Pharmaceutical Manufacturers Association | Directeur/Membre du Conseil | 01/01/2007 |
| ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Young-Jin Kim
| Kelley School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| HANDOK INC. | Health Technology |
| GENEXINE, INC. | Health Technology |
| REZOLUTE, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
pH Pharma Co., Ltd.
 pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Health Technology |
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Sanofi-Aventis Korea Co., Ltd.
 Sanofi-Aventis Korea Co., Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Korea Co., Ltd. provides pharmaceutical research and development services. Its products include prescription medicine, consumer health care, vaccines, and non-prescription medicine. The company founded in April 1991 and is headquartered in Seoul, South Korea. | Health Technology |
The Korea Chamber of Commerce & Industry
The Korea Chamber of Commerce & Industry Miscellaneous Commercial ServicesCommercial Services The Korea Chamber of Commerce & Industry (KCCI) is a business organization that provides resources, publications, events, and networks for its members. The organization is based in Seoul, North Korea and has overseas offices. The KCCI advocates for its members and partners with other organizations to promote bilateral economic cooperation. The KCCI also provides economic data and policy issues publications and hosts business forums and roundtables. Recently, the KCCI hosted a successful business forum with over 600 attendees, including political and business leaders from both countries. The Financial Services Commission identified five bank holding companies and five banks as domestic systemically important banks for 2024, and those identified as D-SIBs are required to set aside an additional common equity capital of 1.0, and the higher loss absorbency requirement will take effect on January 1, 2024. | Commercial Services |
| Handok Jeseok Foundation | |
TRIGR Therapeutics, Inc.
TRIGR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trigr Therapeutics, Inc. engages in pharmaceuticals industry group. The company is headquartered in Irvine, CA. | Health Technology |
| Korea Hoechst Marion Roussel | |
| Korea Pharmaceutical Manufacturers Association | |
| Korean German Society | |
| Korean German Chamber of Commerce & Industry | |
| Hoechst Marion Roussel, Inc. |
